Comparative Pharmacology
Head-to-head clinical analysis: TAVIST 1 versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAVIST 1 versus ZADITOR.
TAVIST-1 vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
1.34 mg orally twice daily; maximum 8.04 mg/day.
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category C
Category C
Antihistamine
Antihistamine